Aarti Drugs Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The GST Department has challenged the Bombay High Court's October 2025 order that had set aside a CGST demand against Aarti Drugs, by filing a Special Leave Petition before the Supreme Court. The original dispute relates to a Show Cause Notice over alleged IGST refund contravention under Rule 96(10) of CGST Rules for FY 2017-18 to FY 2021-22, which had proposed a demand of Rs. 230.70 Crores. The CGST Authority had ultimately demanded Rs. 20.72 Crores as erroneous IGST refund, along with applicable interest and a penalty of Rs. 20.72 Crores, while dropping the larger Rs. 209.98 Crores demand. The company won relief at the High Court level, but that ruling is now under appeal. The company says the financial impact cannot be assessed until the Supreme Court decides the matter, and it will defend its position legally.
Shareholders should note that the original demand of Rs. 20.72 Crores plus equal penalty (totaling ~Rs. 41.44 Crores) is back in play, though the larger Rs. 209.98 Crores demand was already dropped. The outcome is uncertain and sub-judice, so the stock may see some volatility based on Supreme Court proceedings and interim orders.